retatrutide weight loss retatrutide clinical trial status Retatrutide, an experimental weight-loss drug, has not been approved by the New Weight Loss Drug Retatrutide:

has acted as a consultant of Boehringer Ingelheim, Dexcom, Eli Lilly, Novo Nordisk and Sanofi and received speaking fees from Eli Lilly, Novo Nordisk and Sanofi

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (surpass-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 surpass-3 trial

Discontinuing GLP-1 therapy often leads to weight regain, which is why Oana Health focuses on promoting sustainable, long-term approaches for its patients

Each peptide vial used for reconstitution must be labeled For Research Use Only, ensuring it is not administered to patients or individuals outside controlled laboratory studies

They work by mimicking a natural hormone in your body called glucagon-like peptide-1

Why Did North America Dominate the GLP-1 Analogues Market in 2025